IP Library Granted Patent US 12709744
Granted Patent B2
US 12709744 · App. 18/052,454 · Granted Aug 18, 2026

Xylanase variants and polynucleotides encoding same

Inventors: Annette Helle Johansen (Bronshoj, DK); Steffen Danielsen (Stenlose, DK); Frank Winther Rasmussen (Roskilde, DK); Peter Kamp Hansen (Lejre, DK); Roland Alexander Pache (Valby, DK)
Assignee: Novozymes A/S
C12N9/248A21D8/042A23K20/189C12Y302/01136
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12709744
App. No.
18/052,454
Filed
Nov 3, 2022
Granted
Aug 18, 2026
Kind
B2
Art Unit
1655
USPC
426/18
Abstract

The present invention relates to xylanase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; compositions comprising the xylanase variants and methods of using the variants.

Claims (33)

1 . A xylanase variant having xylanase activity and improved thermostability compared to a parent xylanase, wherein the variant has at least 90% sequence identity to SEQ ID NO: 1 and comprises one or more substitutions relative to the parent xylanase, said one or more substitutions occurring at one or more positions corresponding to positions 14, 18, 50, 145, 146, 176, 179, 197, 298 and 299 of SEQ ID NO: 1 and comprising at least one substitution with an amino acid residue selected from the group consisting of C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y, with the proviso that the substituted amino acid residue is different from the naturally-occurring amino acid residue in that position.

2 . The xylanase variant of claim 1 , comprising one or more substitutions selected from the group consisting of Q14K, Q14Y, Q14A, Q14V, Q14W, Q14F, Q14S, Q14P, Q14G, Q14R, Q14M, Q14H, Q14C, Q14D, G18H, G18Y, G18W, G18F, G18C, G18S, G18A, S50H, S50F, S50R, S50K, S50I, S50L, S50Q, S50Y, S50N, S50V, S50M, S50P, S50A, S50C, S50G, S50D, S50E, S50T, H145Y, H145C, H145K, H145A, H145W, E146R, E146H, E146Y, E146F, E146W, E146A, E146K, E146G, E146S, F176H, F176R, F176Y, F176K, F176W, L179D, L179N, L179C, L179A, L179R, L179K, L179S, L179Q, L179W, D197A, D197S, D197Q, D197G, D197P, D197T, D197N, R298Q, R298A, R298E, R298M, R298T, R298N, R298C, R298I, R298D, R298L, R298G, R298W, R298S, R298P, R298Y, P299W, P299A, P299K, P299F, P299Y, P299Q, P299N, P299H, P299E, P299D, P299R, P299M, P299C, P299G and P299S.

3 . A composition comprising the xylanase variant of claim 1 and a formulating agent.

4 . A granule comprising the xylanase variant of claim 1 and a formulating agent, wherein the granule comprises a core particle and one or more coatings.

5 . A composition comprising the xylanase variant of claim 1 and one or more components selected from the group consisting of:

one or more vitamins;

one or more minerals;

one or more amino acids;

one or more phytogenics;

one or more prebiotics;

one or more organic acids; and

one or more plant materials.

6 . A liquid formulation comprising the xylanase variant of claim 1 , wherein the xylanase variant is dosed between 0.01% to 25% w/w of liquid formulation.

7 . The xylanase variant of claim 1 , wherein the variant has at least 90% sequence identity to SEQ ID NO: 1.

8 . The xylanase variant of claim 1 , wherein the variant has at least 95% sequence identity to SEQ ID NO: 1.

9 . The xylanase variant of claim 1 , wherein the variant has at least 96% sequence identity to SEQ ID NO: 1.

10 . The xylanase variant of claim 1 , wherein the variant has at least 97% sequence identity to SEQ ID NO: 1.

11 . The xylanase variant of claim 1 , wherein the variant has at least 98% sequence identity to SEQ ID NO: 1.

12 . The xylanase variant of claim 1 , wherein the variant has at least 99% sequence identity to SEQ ID NO: 1.

13 . The xylanase variant of claim 1 , comprising a substitution selected from Q14K, Q14Y, Q14A, Q14V, Q14W, Q14F, Q14S, Q14P, Q14G, Q14R, Q14M, Q14H, Q14C and Q14D.

14 . The xylanase variant of claim 1 , comprising a substitution selected from G18H, G18Y, G18W, G18F, G18C, and G18S.

15 . The xylanase variant of claim 1 , comprising a substitution selected from S50H, S50F, S50R, S50K, S50I, S50L, S50Q, S50Y, S50N, S50V, S50M, S50P, S50A, S50C, S50G, S50D, S50E and S50T.

16 . The xylanase variant of claim 1 , comprising a substitution selected from H145Y, H145C, H145K, and H145W.

17 . The xylanase variant of claim 1 , comprising a substitution selected from E146R, E146H, E146Y, E146F, E146W, E146K, E146G and E146S.

18 . The xylanase variant of claim 1 , comprising a substitution selected from F176H, F176R, F176Y, F176K and F176W.

19 . The xylanase variant of claim 1 , comprising a substitution selected from L179D, L179N, L179C, L179A, L179R, L179K, L179S, L179Q and L179W.

20 . The xylanase variant of claim 1 , comprising a substitution selected from D197A, D197S, D197Q, D197G, D197P, D197T and D197N.

21 . The xylanase variant of claim 1 , comprising a substitution selected from R298Q, R298A, R298E, R298M, R298T, R298N, R298C, R298I, R298D, R298L, R298G, R298W, R298S, R298P and R298Y.

22 . The xylanase variant of claim 1 , comprising a substitution selected from P299W, P299A, P299K, P299F, P299Y, P299Q, P299N, P299H, P299E, P299D, P299R, P299M, P299C, P299G and P299S.

23 . The xylanase variant of claim 1 , comprising substitutions at positions corresponding to positions 50, 145, 176, 179 and 196 of SEQ ID NO: 1.

24 . The xylanase variant of claim 1 , comprising one or more substitutions selected from S50H, S50F, S50R, S50K, S50I, S50L, S50Q, S50Y, S50N, S50V, S50M, S50P, S50C, S50G, S50D, S50E, S50T, H145Y, H145C, H145K, H145W, F176H, F176R, F176Y, F176K, F176W, L179D, L179N, L179C, L179R, L179K, L179S, L179Q, L179W and D197S.

25 . The xylanase variant of claim 1 , comprising substitutions S50H, H145Y, F176H, L179D and M196L.

26 . A method comprising contacting a plant material with the xylanase variant of claim 1 .